US stocks
Oct 30, 2026

U.S. pharma stocks extend gains, AstraZeneca jumps more than 6% after earnings

U.S. pharmaceutical stocks continued to rise, according to MSX.COM data, with AstraZeneca leading the move after posting quarterly results. The company climbed more than 6% after its earnings release, as third-quarter profit came in above expectations. Other major drugmakers also advanced during the session. Eli Lilly and Gilead Sciences each gained more than 4%, while Amgen rose nearly 3% and Johnson & Johnson added close to 2%. The report said all of these stocks hit record highs intraday. The move kept the broader healthcare and pharmaceutical segment on an upward track in U.S. equities.

350
U.S. pharma stocks extend gains, AstraZeneca jumps more than 6% after earnings
AstraZeneca
Oct 15, 2026

AstraZeneca teams up with insitro on AI drug discovery deal worth up to $1.86 billion

AstraZeneca has entered an AI drug discovery partnership with biotech company insitro, in a deal valued at up to $1.86 billion. Techub, citing Crypto Briefing, reported that the agreement is aimed at using artificial intelligence to speed up the drug discovery process. The partnership brings together a major pharmaceutical company and an AI-focused biotech firm at a time when the use of machine learning in life sciences continues to draw attention. The report also said the collaboration could reshape industry dynamics, though no additional terms were disclosed in the source summary. The announcement centers on the size of the deal, the companies involved, and the role AI is expected to play in accelerating early-stage drug development.

760
AstraZeneca teams up with insitro on AI drug discovery deal worth up to $1.86 billion
US stocks
Sep 29, 2026

US stocks open mixed as uniQure drops 39% and Summit Therapeutics gains 19.2%

US stocks opened mixed, according to market data cited by ChainCatcher from Gate. At the open, the Dow Jones Industrial Average fell 0.1%, the S&P 500 rose 0.13%, and the Nasdaq gained 0.3%. Among individual names, biotech company uniQure fell 39% after 48-month data for its Huntington’s disease gene therapy failed to reach statistical significance. Summit Therapeutics rose 19.2% after AstraZeneca had proposed a $2 billion investment in the company to jointly develop an anticancer drug. The moves highlighted sharp divergence between the broader US equity benchmarks and select biotech stocks at the open.

880
US stocks open mixed as uniQure drops 39% and Summit Therapeutics gains 19.2%